{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "19544975",
  "DateCompleted": {
    "Year": "2009",
    "Month": "07",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "11",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0965-0407",
      "JournalIssue": {
        "Volume": "17",
        "Issue": "8",
        "PubDate": {
          "Year": "2009"
        }
      },
      "Title": "Oncology research",
      "ISOAbbreviation": "Oncol Res"
    },
    "ArticleTitle": "Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer.",
    "Pagination": {
      "StartPage": "383",
      "EndPage": "386",
      "MedlinePgn": "383-6"
    },
    "Abstract": {
      "AbstractText": [
        "The 21 amino acid signaling peptide endothelin-1 is commonly elevated in epithelial ovarian cancer, and it mediates or facilitates much of this cancer's aggressive behavior. Ambrisentan (Letairis; Gilead Sciences Inc.) is an antagonist of endothelin-1 at its cognate receptor that has just been approved to treat pulmonary hypertension. Ambrisentan is a well-tolerated pill taken once daily. In theory, it should retard and inhibit lodgement and establishment of disseminated peritoneal micrometastases after debulking surgery."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA. rekast@email.com"
          }
        ],
        "LastName": "Kast",
        "ForeName": "R E",
        "Initials": "RE"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Oncol Res",
    "NlmUniqueID": "9208097",
    "ISSNLinking": "0965-0407"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Endothelin-1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Phenylpropionates"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyridazines"
    },
    {
      "RegistryNumber": "HW6NV07QEC",
      "NameOfSubstance": "ambrisentan"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Amino Acid Sequence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Chemotherapy, Adjuvant"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "chemistry"
      ],
      "DescriptorName": "Endothelin-1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gynecologic Surgical Procedures"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Sequence Data"
    },
    {
      "QualifierName": [
        "drug therapy",
        "surgery"
      ],
      "DescriptorName": "Neoplasms, Glandular and Epithelial"
    },
    {
      "QualifierName": [
        "drug therapy",
        "surgery"
      ],
      "DescriptorName": "Ovarian Neoplasms"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Phenylpropionates"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Pyridazines"
    }
  ],
  "NumberOfReferences": "27"
}